Current Environment:

Alert

ENFit Feeding Tube Adapters

GI Feeding Tube Users: if you do not have ENFit tubes, you may need an adapter to deliver feeds or medications. Contact your pharmacy or home care company.

Summary

The objective of the Pediatric Gastroparesis Registry is to create a national prospective registry of children and adolescents with gastroparesis and gastroparesis-like syndrome (symptoms of gastroparesis but normal gastric emptying).

Conditions

Gastroparesis, Gastroparesis-like Syndrome

Recruitment Status

Recruiting

Detailed Description

In the Pediatric Gastroparesis Registry (PGpR), we will collect detailed epidemiological, clinical, psychological, and patient outcome data with the goal of classifying patients with gastroparesis and gastroparesis-like syndromes into pathophysiologically defined phenotypes. The Primary Objective is to create a national prospective registry of children and adolescents with gastroparesis and gastroparesis-like syndrome (symptoms of gastroparesis but normal gastric emptying) to include: Demographic, clinical, psychological, nutritional characteristics, physiological measures, and serial assessments of symptoms over 3 years while receiving clinical care; Establish a Biorepository of plasma, serum, peripheral blood mononuclear cells (PBMC), GI mucosal biopsies (in those undergoing upper GI endoscopy), urine and stool collected from the children and adolescents in this registry which will allow for future analyses such as cytokines, bacterial DNA and microbiome to investigate the etiology and pathogenesis of gastroparesis in children. Secondary Objectives: To determine what factors, if any, play a role in the outcomes of children who do not improve within two years of diagnosis To assess the spectrum of symptom severity of the cardinal gastroparesis symptoms: nausea, vomiting, early satiety, postprandial fullness (and upper abdominal pain, if present) in children with gastroparesis To assess several areas of gastric motility in pediatric patients with symptoms of gastroparesis (e.g., intragastric meal distribution, global gastric emptying) To capture the clinical symptomatic course (outcome) of pediatric patients followed in the registry To determine whether gastroparesis symptoms are correlated with gastric emptying in a pediatric population To characterize abdominal pain in patients with gastroparesis and gastroparesis-like syndrome by using questionnaires, water load satiety testing and quantitative sensory testing (QST) Determine the prevalence of hypermobility spectrum disorders in pediatric patients with gastroparesis To determine if the volume of water consumed during the water load satiety test is an indirect measure of gastric accommodation To determine if the water load satiety test is associated with an increased severity of gastroparesis symptoms (fullness, bloating, abdominal pain, etc). To compare the intragastric meal distribution during scintigraphy to symptoms of early satiety, postprandial fullness in patients with symptoms of gastroparesis Define immune cell profiles, cytokine induction and epigenetic changes in diabetic and idiopathic gastroparesis

Eligibility Criteria

Inclusion Criteria:

Cardinal symptoms of gastroparesis of at least 12 weeks duration. Cardinal symptoms of gastroparesis are the constellation of some combination of: nausea, vomiting, early satiety, postprandial fullness; symptoms sometimes may be accompanied by upper abdominal pain
An etiology of either diabetic, idiopathic, or post-fundoplication gastroparesis or gastroparesis-like disorder (symptoms of gastroparesis but normal gastric emptying; see below)

Gastric emptying scintigraphy (GES) of solids using the 4-hour Egg Beaters® protocol (or equivalent generic liquid egg white meal) within the last 12 months with either:

Abnormal gastric emptying rate defined as an abnormal 2-hour (>60% retention) and/or 4-hour (>10% retention) result based on a 4-hour scintigraphic gastric emptying study. (This group will comprise ~75% of patients in the registry)
Patients with a normal gastric emptying rate, but who have symptoms of gastroparesis. (This group will comprise ~25% of patients in the registry)
Age at least 5 years, and under 18 years at initial screening visit

Exclusion Criteria:

Inability to comply with or complete the scintigraphic gastric emptying test (including allergy to eggs)
Pregnancy
Autism spectrum disorder, significant developmental delay, psychosis, or a history of bipolar disorder (because of inability to complete the gastroparesis symptom questionnaires: 24-hour recall and gastroparesis cardinal symptom questionnaire (the latter to be completed during the scintigraphy if possible)
Use of narcotic analgesics greater than three days per week
Presence of conditions associated with GI mucosal disease (e.g., inflammatory bowel disease, known eosinophilic gastroenteritis or eosinophilic esophagitis)

Presence of any other condition that could cause delayed gastric emptying including:

Gastrointestinal obstruction confirmed by EGD, UGI, or abdominal CT
Primary neurological conditions that can cause nausea and vomiting such as increased intracranial pressure, space occupying or inflammatory/infectious lesions
Acute or chronic renal failure (abnormal creatinine for age) and/or on hemodialysis or peritoneal dialysis
Acute liver failure
Advanced liver disease (features of portal hypertension)
Clinically significant congenital heart disease (i.e., vagal injury during cardiac repair)
History of esophageal, gastric or bowel surgery excepting prior fundoplication
Metabolic disease including mitochondrial disease and inborn errors of metabolism
Chronic lung disease (including cystic fibrosis)
A serious chronic medical condition (e.g., cystic fibrosis)
Use of medications that can affect motility during the gastric emptying study
Any other condition, which in the opinion of the investigator, could explain the symptoms or interfere with study requirements
Inability to obtain informed consent/assent

Gender

All

Min Age

5 Years

Max Age

17 Years

Download Date

February 22, 2022

Principal Investigator

N/A

Primary Contact Information

Laura Miriel

410-955-4165

laura.miriel@jhu.edu

For more information on this trial, visit clinicaltrials.gov.

Contact

For more information and to contact the study team: